2bxf: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
No edit summary
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
Human serum albumin (HSA) is an abundant plasma protein that binds a, remarkably wide range of drugs, thereby restricting their free, active, concentrations. The problem of overcoming the binding affinity of lead, compounds for HSA represents a major challenge in drug development., Crystallographic analysis of 17 different complexes of HSA with a wide, variety of drugs and small-molecule toxins reveals the precise, architecture of the two primary drug-binding sites on the protein, identifying residues that are key determinants of binding specificity and, illuminating the capacity of both pockets for flexible accommodation., Numerous secondary binding sites for drugs distributed across the protein, have also been identified. The binding of fatty acids, the primary, physiological ligand for the protein, is shown to alter the polarity and, increase the volume of drug site 1. These results clarify the, interpretation of accumulated drug binding data and provide a valuable, template for design efforts to modulate the interaction with HSA.
Human serum albumin (HSA) is an abundant plasma protein that binds a remarkably wide range of drugs, thereby restricting their free, active concentrations. The problem of overcoming the binding affinity of lead compounds for HSA represents a major challenge in drug development. Crystallographic analysis of 17 different complexes of HSA with a wide variety of drugs and small-molecule toxins reveals the precise architecture of the two primary drug-binding sites on the protein, identifying residues that are key determinants of binding specificity and illuminating the capacity of both pockets for flexible accommodation. Numerous secondary binding sites for drugs distributed across the protein have also been identified. The binding of fatty acids, the primary physiological ligand for the protein, is shown to alter the polarity and increase the volume of drug site 1. These results clarify the interpretation of accumulated drug binding data and provide a valuable template for design efforts to modulate the interaction with HSA.


==Disease==
==Disease==
Line 16: Line 16:
[[Category: Homo sapiens]]
[[Category: Homo sapiens]]
[[Category: Single protein]]
[[Category: Single protein]]
[[Category: Bhattacharya, A.A.]]
[[Category: Bhattacharya, A A.]]
[[Category: Curry, S.]]
[[Category: Curry, S.]]
[[Category: Ghuman, J.]]
[[Category: Ghuman, J.]]
[[Category: Petitpas, I.]]
[[Category: Petitpas, I.]]
[[Category: Zunszain, P.A.]]
[[Category: Zunszain, P A.]]
[[Category: DZP]]
[[Category: DZP]]
[[Category: albumin]]
[[Category: albumin]]
Line 30: Line 30:
[[Category: transport protein]]
[[Category: transport protein]]


''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Feb 3 10:28:55 2008''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 16:42:44 2008''

Revision as of 17:42, 21 February 2008

File:2bxf.gif


2bxf, resolution 2.95Å

Drag the structure with the mouse to rotate

HUMAN SERUM ALBUMIN COMPLEXED WITH DIAZEPAM

OverviewOverview

Human serum albumin (HSA) is an abundant plasma protein that binds a remarkably wide range of drugs, thereby restricting their free, active concentrations. The problem of overcoming the binding affinity of lead compounds for HSA represents a major challenge in drug development. Crystallographic analysis of 17 different complexes of HSA with a wide variety of drugs and small-molecule toxins reveals the precise architecture of the two primary drug-binding sites on the protein, identifying residues that are key determinants of binding specificity and illuminating the capacity of both pockets for flexible accommodation. Numerous secondary binding sites for drugs distributed across the protein have also been identified. The binding of fatty acids, the primary physiological ligand for the protein, is shown to alter the polarity and increase the volume of drug site 1. These results clarify the interpretation of accumulated drug binding data and provide a valuable template for design efforts to modulate the interaction with HSA.

DiseaseDisease

Known diseases associated with this structure: Analbuminemia OMIM:[103600], Dysalbuminemic hyperthyroxinemia OMIM:[103600], Dysalbuminemic hyperzincemia OMIM:[103600]

About this StructureAbout this Structure

2BXF is a Single protein structure of sequence from Homo sapiens with as ligand. Known structural/functional Site: . Full crystallographic information is available from OCA.

ReferenceReference

Structural basis of the drug-binding specificity of human serum albumin., Ghuman J, Zunszain PA, Petitpas I, Bhattacharya AA, Otagiri M, Curry S, J Mol Biol. 2005 Oct 14;353(1):38-52. PMID:16169013

Page seeded by OCA on Thu Feb 21 16:42:44 2008

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA